Share this video  

GU Cancers 2020 | OSPREY: PSMA-targeted PET-CT imaging in prostate cancer

Frédéric Pouliot, MD, PhD, FRCSC, Research Center CHU de Quebec, Université Laval, Quebec, Canada, discusses a subanalysis of metastases detection rates by PSMA-targeted PET-CT in patients with prostate cancer from the OSPREY trial (NCT02981368). This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.